Background
==========

Non-traumatic fracture, spontaneous or occurring al low energy, is defined as a lesion caused by falling on a flat surface or due to an unbalanced center of gravity. It is usually seen in the elderly and the high rate of repeated fractures imposes a heavy burden on patients, their families, and society \[[@b1-medscimonit-21-3875],[@b2-medscimonit-21-3875]\]. However, the pathology and etiology of non-traumatic fracture remain mysterious; like others disease, genetic, biological, and environmental factors are suspected and studied widely. Thiazolidinedione drugs, type 2 diabetes mellitus, chronic inflammation, and osteoporosis have been proved to be related to fracture \[[@b3-medscimonit-21-3875]--[@b5-medscimonit-21-3875]\]. Fragility fracture is the most serious outcome of osteoporosis, and over-expression of osteopontin (OPN) is considered as a risk factor for osteoporosis \[[@b6-medscimonit-21-3875]\].

In 1979, Senger et al. discovered secreted phosphoprotein 1 (SPP1) \[[@b7-medscimonit-21-3875]\], also called osteopontin (OPN), which is a kind of secreted protein in malignant epithelial cells. It is encoded by *SPP1* gene located in chromosome 4. Animal osteoclasts, osteogenesis, vascular smooth muscle cell, and endothelial cell all can identify *SPP1* expression \[[@b8-medscimonit-21-3875],[@b9-medscimonit-21-3875]\]. SPP1, a non-collagenous protein of bone, widely exists in extracellular and intercellular sites in inflamed areas and bone tissue and can utilize polyaspartic acid salt and different receptor connection sequences to adsorb bone mineral as the cell adhesion protein \[[@b10-medscimonit-21-3875]\]. Many studies showed that *SPP1* is the moderator of crystal growth and nucleogenesis, and plays an important role in promoting the function exertion of osteoclasts \[[@b11-medscimonit-21-3875]--[@b13-medscimonit-21-3875]\]. In addition, when cell damage occurs and macrophages and T lymphocytes gather in the area of inflammation or infection, the expression quantity of *SPP1* increases \[[@b14-medscimonit-21-3875]\]. The above-mentioned evidence suggests that *SPP1* is important for the development and function of bone.

Although fractures are a common orthopedic problem, there is little research about the correlation between *SPP1* polymorphism and fractures. Research shows that extracellular *SPP1* benefits the movement, fusion, and reabsorption of osteoclasts to compensate for the loss of sectional endogenous *SPP1* \[[@b15-medscimonit-21-3875]\]. Therefore, this study analyzed the correlation between single-nucleotide polymorphisms (SNP) in *SPP1* rs4754 and rs6840362 polymorphisms and fracture to provide some theoretical foundations for the mechanism of fracture.

Material and Methods
====================

The case and the control groups
-------------------------------

This case-control study investigated the correlation between *SPP1* polymorphisms and fracture. The research subjects were all unrelated Han Chinese. Both groups were informed about the study and provided signed informed consent. Afterwards, the orthopedic investigators, who had been trained professionally, recorded the relevant information of all subjects and collected blood samples. This research was reviewed and authorized by the Ethics Committee of the Chinese PLA General Hospital. The process of sample collection was conducted according to the national ethics criteria for human genome research.

The 130 patients in the case group were non-traumatic fracture patients in the Orthopedics Department of the Chinese PLA General Hospital during October 2012 to January 2014, including 82 postmenopausal women and 48 men. Their age range was 52--78 years, with average age of 63.58±10.29 years. The cases were checked by X-ray and read and diagnosed by an orthopedist or trained radiologist. We excluded patients who had calcium or phosphorus metabolism diseases, pathological fractures caused by traumatic fracture, or cancer and the other bone diseases. Patient clinical data were also recorded, including sex, age, symptoms, part affected, and severity of fracture, and then entered the data into an Excel form.

The healthy control group included healthy people who had a medical examination and were also in the Chinese PLA General Hospital during the same period. There were a total of 107 people, including 73 postmenopausal women and 34 men, ages 50--73 years. The inclusion criteria for the healthy control group were healthy examinees with normal physical examination results. They were matched with the case group for age and sex without medical history. The patients with tumor, diabetes, hepatic disease, or severe osteoporosis (past or present) were excluded.

Methods
-------

### DNA extraction

We collected 3 ml of venous blood from every subject into an anticoagulative tube with ethylene diamine tetraacetic acid (EDTA) after obtaining informed consent. According to the manufacturer's instructions, peripheral blood leucocyte genome DNA of all samples was extracted using Beijing TIANGEN biochemical blood genome DNA extraction kit, and then stored in --20°C a refrigerator for later use.

### SPP1 genotyping

Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was applied for the genotyping of *SSP1* rs4754, rs6840362 polymorphisms. For primer design, we searched GeneBank database on the NCBI website to refer to the published *SPP1* gene sequence in human chromosome 4. Complying with general primer design principles, we designed the PCR primers using Primer Premier 5.0 software. The detailed sequences are listed in [Table 1](#t1-medscimonit-21-3875){ref-type="table"}. A total of 25 μl solution in PCR system included 1.0 μl DNA template, each 1.0 μl of forward and reverse primers, 2.5 μl 10×buffer, 1.5 μl MgC1~2~, 1.0 μl dNTPs, 0.5 μl Taq enzyme, and 16.5 μl ddH~2~O. The amplification conditions of PCR were 95°C pre-denaturation for 5 min; followed by 38 cycles of 94°C degeneration for 30 s, 60°C annealing for 60 s, 72°C extension for 60 s, and finally 72°C extension for 10 min. The PCR products were checked in 1% agarose gel electrophoresis (AGE).

Enzyme reaction system was a volume of 20 μl, including 4 μl restriction enzyme (*Bpi*I for rs4754 and *Alu*I for rs6840362), 8 μl PCR products, 2 μl 10×buffer solution, and 6 μl double-distilled water. Then the mixture was digested in a 37°C water bath overnight. The enzyme-digested products were separated by 3% AGE and we observed the final outcome in the imaging system.

Statistical analysis
--------------------

PASW Statistics 18.0 software was used to analyze the data and *P*\<0.05 was considered as the statistical significance. Measurement data are expressed by x\_±s and%. The genotype frequencies in the control group were tested by χ^2^ to confirm if their distribution matched Hardy-Weinberg equilibrium (HWE). The comparison of genotypes, alleles and haplotypes between two groups were tested by chi-square test. Linkage disequilibrium (LD) and its correlation coefficient (D' value) were calculated with HaploView. Haplotypes were analyzed between rs4754, rs6840362 if LD existed. The effect of *SSP1* polymorphisms on fracture was evaluated with odd ratio (OR) and 95% confidence interval (CI).

Results
=======

General conditions of research objects
--------------------------------------

This study collected a total of 239 subjects that met inclusion requirements, with complete data in case and control groups. In the case group, women accounted for 63.08%, and the sex ratio was 1.71:1 (women: men); the group of 109 healthy people included 75 women and 34 men. There was no significant different between the 2 groups by sex. The controls (mean age 62.13±9.24 years) were similar to the cases (63.58±10.29) in terms of age (*P*\>0.05). Furthermore, the genotypes distribution of *SSP1* polymorphisms both conformed to HWE, suggesting that our population similar in genetic background to a Mendelian population.

The distribution of *SPP1* gene SNP in case and control groups
--------------------------------------------------------------

From [Table 2](#t2-medscimonit-21-3875){ref-type="table"}, we could see clearly that the TT, TC, and CC genotype frequencies in rs4754 were 42.31%, 46.92%, and 10.77% in the case group and 54.13%, 41.28%, and 4.59%, respectively, in the control group. The C and T allele frequencies were 65.77% and 34.23% in the case group, and 74.77% and 25.23%, respectively, in the control group. The TT genotype and T allele distributions had statistically significant difference in the 2 groups (*P*=0.04, 0.03) and their carriers were easily subject to fractures compared with people with CC genotype and C allele (TT *vs.* CC: OR=3.00, 95%CI=1.02--8.89; T *vs.* C: OR=1.54, 95%CI=1.04--2.30). The genotypes frequencies of rs6840362 were 82.30%, 13.85%, and 3.85% in cases and 78.90%, 18.35%, and 2.75% in controls, respectively. There were no significant differences between the 2 groups based on genotypes (*P*=0.36, 0.69) or was allele (*P*=0.69).

Haplotype analysis of *SPP1* rs4754, rs6840362 polymorphisms
------------------------------------------------------------

LD of *SPP1* rs4754 and rs6840362 was analyzed by HaploView software. Strong LD was discovered between them (D'=1.0, r^2^=0.227) and 3 haplotypes were identified in our population, namely C-C, C-T, and T-T (rs6840362-rs4754) ([Table 3](#t3-medscimonit-21-3875){ref-type="table"}). The frequencies of C-C, C-T, and T-T haplotype were 65.77%, 23.46%, and 10.77% in case group, and 74.77%, 13.30%, and 11.93%, respectively, in the control group. The distributions of C-T haplotype had obvious difference between the 2 groups (*P*=0.01), which indicated that it could increase the risk of fractures (OR=2.01, 95%CI=1.23--3.28).

Discussion
==========

SPP1 was first found as an acidic protein of converting specificity, and later was found to be expressed in bone. It serves as a potential bridge connecting osteocytes and hydroxyapatite, which is why human SPP1 (hSPP1) is also called OPN \[[@b16-medscimonit-21-3875]\]. This protein is rich in arginine, glutamic acid, and serine, and includes 1 N-glycosylation, 5--6 O-glycosylation side chains, several serine phosphorylation sites, and threonine phosphorylation sites \[[@b16-medscimonit-21-3875],[@b17-medscimonit-21-3875]\]. Studies show that *SPP1* inhibits the formation of calcium oxalate crystals in urine production, which effectively protects kidney from calcium deposits and urinary calculus \[[@b18-medscimonit-21-3875]\]. Hasegawa et al. has suggested that *OPN* is highly expresses in osteoarthritis (OA) and synovial fluid \[[@b19-medscimonit-21-3875]\]. Sanchez et al. demonstrated that the expression of *OPN* in osteosclerosis areas of subchondral bone in OA patients is clearly higher than in the normal group \[[@b20-medscimonit-21-3875]\]. Sakata et al. verified that serum osteopontin cultivated by stem cells is an autoantigen of OA and rheumatoid arthritis (RA) \[[@b21-medscimonit-21-3875]\]. *SPP1* is a low phosphorylated protein with 5500 molecular weight in preosteoblasts and it may be related to the formation of bone matrix \[[@b22-medscimonit-21-3875]\]. Osteoblasts can synthesize the high phosphorylated proteins and take part in regulating the growth of light apatite crystal, so that OPN is regarded as a sign of osteoblast maturation and differentiation \[[@b23-medscimonit-21-3875]\]. In addition, the amino terminal of SPP1 is related to exocrinosity, and carboxy terminal participates in regulating the adhesion function \[[@b24-medscimonit-21-3875]\].

OPN is a kind of matrix protein found in multiple tissues composed of collagen and non-collagen, and *SPP1* is an important component of the latter. *SPP1*, which is an important extracellular matrix protein, is also an important cytokine. It plays a major role in the process of diffusion and movement between cells, adherence of crossing cytoplasm, mineralization and reestablishment of bone tissue, immunoregulation, and signal transduction. Some foreign scholars have found that *SPP1* polymorphisms also influence urinary calculus. Gao et al. tested *SPP1* polymorphism by TaqMan probe technique and analyzed the relationship between *SPP1* polymorphism and urinary calculus; the results showed that *SPP1* A9402G polymorphism might be a genetic marker and risk factor for forming calculus \[[@b25-medscimonit-21-3875]\]. Later, Gao et al. also discovered an obvious correlation between 2 new SNPs in the *SPP1* promoter region and the risk of kidney stones \[[@b26-medscimonit-21-3875]\]. Liu et al., in a study of the correlation between 3 SNPs of the *SPP1* gene promoter region and the risk of calcium kidney stones in Taiwan, proved that *SPP1* gene -156delG/G polymorphism can be used as a genetic marker to check for risk of calcium kidney stones \[[@b27-medscimonit-21-3875]\]. Miyazak et al. showed that *SPP1* polymorphism is involved in the pathogenetic process of lupus nephritis \[[@b28-medscimonit-21-3875]\]. These study results are not completely consistent, and the correlation between *SPP1* gene polymorphism and several diseases has ethnic heterogeneity.

In this study, genotypes and allele frequencies of rs6840362 polymorphism had no statistically significant difference between the group of patients with fractures and the healthy control group. However, this study only aimed at the Han population in northern China. Therefore, we need to get further verification with larger sample size and more ethnic groups to determine whether rs6840362 polymorphism is related to fracture in other regions. In contrast, we found that the genotype and allele distributions of rs4754 polymorphism had statistical difference between the 2 groups in this study. Moreover, the result was verified by study of the correlation between haplotype of *SPP1* rs6840362, rs4754 polymorphisms, and fracture, in which C~rs6840362~-T~rs4754~ haplotype was discovered to obviously increase the risk fracture in older adults. Results of this article prove that *SPP1* gene polymorphisms are associated with the occurrence of fractures.

Conclusions
===========

The results of the present study support the correlation between *SPP1* polymorphisms and fracture in the Han population of north China. Nevertheless, research with larger sample scale and different populations is required to enrich the study results. It will be important to check all joints and bones of the body by zeugmatography to achieve the aims of precaution, early diagnosis, and timely treatment.
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###### 

Primer sequences of *SPP1* gene in rs4754, rs6840362.

  SNP                                        Primer sequence
  ----------- ------------------------------ ------------------------------
  rs4754      For.                           5′-TTCCCGGCCATCTTAATTTTCA-3′
  Rev.        5′-AAAACTTCGGTTGCTGGCAGGT-3′   
  rs6840362   For.                           5′-CCGTGGGAAGGACAGTTATG-3′
  Rev.        5′-TTTAATTGACCTCAGAAGATG-3′    

###### 

Frequency comparisons of genotypes and alleles in *SPP1* gene polymorphisms.

  Genotype/allele   Case, n=130 (%)   Control, n=109 (%)   χ2     *P*    OR (95% CI)
  ----------------- ----------------- -------------------- ------ ------ -------------------
  rs4754                                                                 
   CC               55 (42.31)        59 (54.13)           --     --     1.00
   TC               61 (46.92)        45 (41.28)           1.91   0.17   1.45 (0.85--2.48)
   TT               14 (10.77)        5 (4.59)             4.22   0.04   3.00 (1.02--8.89)
   C                171 (65.77)       163 (74.77)          --     --     1.00
   T                89 (34.23)        55 (25.23)           4.56   0.03   1.54 (1.04--2.30)
  rs6840362                                                              
   CC               107 (82.30)       86 (78.90)           --     --     1.00
   CT               18 (13.85)        20 (18.35)           0.83   0.36   0.72 (0.36--1.45)
   TT               5 (3.85)          3 (2.75)             0.16   0.69   1.34 (0.31--5.76)
   C                232 (89.23)       192 (88.07)          --     --     1.00
   T                28 (10.77)        26 (11.93)           0.16   0.69   0.89 (0.51--1.57)

###### 

Analyses of LD and haplotypes in *SPP1* rs4754, rs6840362 polymorphisms.

  Haplotype SNP1-SNP2   Case group 2 n=260 (%)   Control group 2 n=218 (%)   χ2     *P*    OR (95% CI)
  --------------------- ------------------------ --------------------------- ------ ------ -------------------
  CC                    171 (65.77)              163 (74.77)                 --     --     1.00
  CT                    61 (23.46)               29 (13.30)                  7.87   0.01   2.01 (1.23--3.28)
  TT                    28 (10.77)               26 (11.93)                  0.01   0.93   1.03 (0.58--1.83)

SNP1 -- rs6840362; SNP2 -- rs4754.
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